Plumb Pharmaceuticals

Plumb Pharmaceuticals is a private, preclinical-stage biotech founded in 2016 to commercialize its Advanced Quantload (AQL™) platform for ultra-long-acting drug delivery. Its lead program is an injectable, subcutaneous naltrexone formulation for opioid use disorder designed to last significantly longer than the current market leader, Vivitrol®, with a potentially improved tolerability profile. The company has secured seed financing and holds key patents for its liposome-based technology, positioning it to address major compliance challenges in chronic conditions like addiction and pain.

Advanced Quantload (AQL™): A two-step liposome platform for ultra-sustained drug release. Step 1 efficiently encapsulates and purifies a loading base. Step 2 actively loads drug via ion-exchange. The system enables high drug payloads and release durations measured in months.

Plumb's direct competitor is Alkermes' Vivitrol (monthly naltrexone). Other competitors include opioid dependence treatments using buprenorphine (e.g., Sublocade) and naltrexone implants used internationally. Plumb's differentiation hinges on a longer duration from a less invasive subcutaneous injection with potentially better tolerability.